|
|
|
Artane advertisement, 1973. Hospital & Community Psychiatry, Vol. 24, No. 2. The new-day constant for drug-induced parkinsonism: Artane® trihexyphenidyl HCl Non-cumulative action makes each day of therapy a new day That's why Artane is ideally suited for the patient on long-term phenothiazine therapy. In economical tablets or Sequels Sustained Release Capsules*, it offers you more than the rapid reversal of extrapyramidal symptoms. Usually there is no drug buildup to cause undue toxicity in prolonged therapy. Minimal atropine-like side effects. Accurate dosage titration in adjunctive use. And, to minimize missed doses and anxiety in outpatient therapy -- one-dose all-day control or prevention with Sequels*. For hospitalized or ambulatory patients, Artane has the "constant" they need. Effective non-cumulative action. *INDICATIONS FOR ARTANE SEQUELS: Based on a review of this drug in sustained release form by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: Probably effective as an adjunct in the therapy of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic) and for the use in the prevention or control of extrapyramidal disorders due to central nervous system drugs such as reserpine and phenothiazines. Lederle Laboratories, A Division of American Cyanamid Company, Pearl River, New York 10965 |